Bayer and Burrill set up venture capital fund
This article was originally published in Clinica
Bayer Innovation, a subsidiary of Bayer, is to throw its weight behind a new $50 million venture capital fund. The company is being formed with life sciences merchant bank Burrill & Company and will be called Burrill Diagnostics Capital Fund. There will be an initial closing of $25 million, with further fundraising expected to be completed by June of this year.